DK1394178T3 - Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment - Google Patents

Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment

Info

Publication number
DK1394178T3
DK1394178T3 DK03022727T DK03022727T DK1394178T3 DK 1394178 T3 DK1394178 T3 DK 1394178T3 DK 03022727 T DK03022727 T DK 03022727T DK 03022727 T DK03022727 T DK 03022727T DK 1394178 T3 DK1394178 T3 DK 1394178T3
Authority
DK
Denmark
Prior art keywords
mbp
residues
levels
amino acid
synthetic peptides
Prior art date
Application number
DK03022727T
Other languages
Danish (da)
English (en)
Inventor
Kenneth G Warren
Ingrid Catz
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Application granted granted Critical
Publication of DK1394178T3 publication Critical patent/DK1394178T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK03022727T 1997-04-04 1998-04-03 Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment DK1394178T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2201841A CA2201841C (en) 1997-04-04 1997-04-04 Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
PCT/CA1998/000290 WO1998045327A1 (en) 1997-04-04 1998-04-03 Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1394178T3 true DK1394178T3 (da) 2008-05-26

Family

ID=4160340

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03022727T DK1394178T3 (da) 1997-04-04 1998-04-03 Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment
DK98914725T DK0970121T3 (da) 1997-04-04 1998-04-03 Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98914725T DK0970121T3 (da) 1997-04-04 1998-04-03 Peptidfragmenter af myelin-basisk-protein, deres farmaceutiske sammensætninger og deres anvendelse i behandling af multipel sklerose

Country Status (20)

Country Link
EP (2) EP0970121B1 (cs)
JP (1) JP4173557B2 (cs)
AT (2) ATE386941T1 (cs)
AU (1) AU751303B2 (cs)
CA (2) CA2494338C (cs)
CY (2) CY1107445T1 (cs)
CZ (1) CZ299535B6 (cs)
DE (2) DE69839163T2 (cs)
DK (2) DK1394178T3 (cs)
ES (2) ES2299657T3 (cs)
HU (1) HU226768B1 (cs)
NO (1) NO325018B1 (cs)
NZ (1) NZ338091A (cs)
PL (1) PL191965B1 (cs)
PT (2) PT1394178E (cs)
RO (1) RO119303B1 (cs)
RU (1) RU2198893C2 (cs)
SK (1) SK285815B6 (cs)
UA (1) UA60331C2 (cs)
WO (1) WO1998045327A1 (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401484A1 (en) 2001-06-11 2004-03-31 Transition Therapeutics Inc. Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
RU2261713C1 (ru) * 2004-04-27 2005-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения тяжелой формы острого оптического неврита у пациентов с рассеянным склерозом
EP2488196B1 (en) 2009-10-12 2015-12-16 LIFEBio Laboratories LLC Composition for treatment of multiple sclerosis
RU2646817C1 (ru) * 2016-12-27 2018-03-07 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид из состава тяжелой цепи иммуноглобулина человека, пригодный для лечения рассеянного склероза

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021611C1 (ru) * 1991-04-19 1994-10-15 Михайленко Анатолий Андреевич Способ диагностики рассеянного склероза
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
WO1993021222A1 (en) * 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
WO1996012737A2 (en) * 1994-10-25 1996-05-02 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
HUP0000812A3 (en) 2000-10-30
EP1394178A1 (en) 2004-03-03
PT970121E (pt) 2008-09-22
RU2198893C2 (ru) 2003-02-20
AU751303B2 (en) 2002-08-15
EP0970121A1 (en) 2000-01-12
DE69839694D1 (de) 2008-08-21
DK0970121T3 (da) 2008-10-20
PL191965B1 (pl) 2006-07-31
ES2299657T3 (es) 2008-06-01
CZ299535B6 (cs) 2008-08-27
HK1063805A1 (en) 2005-01-14
NO994806D0 (no) 1999-10-01
PL336085A1 (en) 2000-06-05
SK132999A3 (en) 2000-06-12
RO119303B1 (ro) 2004-07-30
CA2494338C (en) 2007-07-17
DE69839163D1 (de) 2008-04-03
ES2307317T3 (es) 2008-11-16
NZ338091A (en) 2001-10-26
DE69839163T2 (de) 2009-02-12
ATE400582T1 (de) 2008-07-15
NO325018B1 (no) 2008-01-14
EP1394178B1 (en) 2008-02-20
CY1107445T1 (el) 2012-12-19
CA2201841C (en) 2010-01-26
CY1108239T1 (el) 2014-02-12
UA60331C2 (uk) 2003-10-15
WO1998045327A1 (en) 1998-10-15
JP4173557B2 (ja) 2008-10-29
HUP0000812A2 (hu) 2000-09-28
EP0970121B1 (en) 2008-07-09
SK285815B6 (sk) 2007-08-02
ATE386941T1 (de) 2008-03-15
CZ9903464A3 (cs) 2000-11-15
AU6913098A (en) 1998-10-30
CA2494338A1 (en) 1998-10-04
NO994806L (no) 1999-12-06
CA2201841A1 (en) 1998-10-04
HU226768B1 (en) 2009-09-28
PT1394178E (pt) 2008-04-15
JP2001518885A (ja) 2001-10-16

Similar Documents

Publication Publication Date Title
DK0789709T3 (da) Peptidspecificitet af anti-myelin basisprotein og administrationen af myelin basisproteinpeptider til dissemineret sklerose patienter
ATE425181T1 (de) Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
FI941860A0 (fi) Keskushermoston pesäkekovettumatautiaivo-selkäydinnesteestä peräisin olevan antimyeliiniemäsproteiinin synteettinen peptidispesifisyys
DK1394178T3 (da) Fremgangsmåde til fastlæggelse af den terapeutiske aktivitet af et MBP-fragment
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
LV11816A (lv) Implantejama zalu forma
WO1995030435A3 (en) Compositions and treatment for multiple sclerosis
NZ335835A (en) Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
EP0723016A3 (en) Leukocyte activation factor